Madenci Arin L, Fisher Stacey, Diller Lisa R, Goldsby Robert E, Leisenring Wendy M, Oeffinger Kevin C, Robison Leslie L, Sklar Charles A, Stovall Marilyn, Weathers Rita E, Armstrong Gregory T, Yasui Yutaka, Weldon Christopher B
Arin L. Madenci and Christopher B. Weldon, Boston Children's Hospital and Harvard Medical School; Arin L. Madenci, Brigham and Women's Hospital and Harvard Medical School; Lisa R. Diller and Christopher B. Weldon, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Stacey Fisher and Yutaka Yasui, University of Alberta, Edmonton, Alberta, Canada; Robert E. Goldsby, School of Medicine, University of California, San Francisco, San Francisco, CA; Wendy M. Leisenring, Fred Hutchinson Cancer Research Center, Seattle, WA; Kevin C. Oeffinger and Charles A. Sklar, Memorial Sloan-Kettering Cancer Center, New York, NY; Leslie L. Robison and Gregory T. Armstrong, St Jude Children's Research Hospital, Memphis, TN; and Marilyn Stovall and Rita E. Weathers, The University of Texas MD Anderson Cancer Center, Houston, TX.
J Clin Oncol. 2015 Sep 10;33(26):2893-900. doi: 10.1200/JCO.2015.61.5070. Epub 2015 Aug 10.
For adult survivors of childhood cancer, knowledge about the long-term risk of intestinal obstruction from surgery, chemotherapy, and radiotherapy is limited.
Intestinal obstruction requiring surgery (IOS) occurring 5 or more years after cancer diagnosis was evaluated in 12,316 5-year survivors in the Childhood Cancer Survivor Study (2,002 with and 10,314 without abdominopelvic tumors) and 4,023 sibling participants. Cumulative incidence of IOS was calculated with second malignant neoplasm, late recurrence, and death as competing risks. Using piecewise exponential models, we assessed the associations of clinical and demographic factors with rate of IOS.
Late IOS was reported by 165 survivors (median age at IOS, 19 years; range, 5 to 50 years; median time from diagnosis to IOS, 13 years) and 14 siblings. The cumulative incidence of late IOS at 35 years was 5.8% (95% CI, 4.4% to 7.3%) among survivors with abdominopelvic tumors, 1.0% (95% CI, 0.7% to 1.4%) among those without abdominopelvic tumors, and 0.3% (95% CI, 0.1% to 0.5%) among siblings. Among survivors, abdominopelvic tumor (adjusted rate ratio [ARR], 3.6; 95% CI, 1.9 to 6.8; P < .001) and abdominal/pelvic radiotherapy within 5 years of cancer diagnosis (ARR, 2.4; 95% CI, 1.6 to 3.7; P < .001) increased the rate of late IOS, adjusting for diagnosis year; sex; race/ethnicity; age at diagnosis; age during follow-up (as natural cubic spline); cancer type; and chemotherapy, radiotherapy, and surgery within 5 years of cancer diagnosis. Developing late IOS increased subsequent mortality among survivors (ARR, 1.8; 95% CI, 1.1 to 2.9; P = .016), adjusting for the same factors.
The long-term risk of IOS and its association with subsequent mortality underscore the need to promote awareness of this complication among patients and providers.
对于童年癌症成年幸存者,关于手术、化疗和放疗导致肠梗阻的长期风险的了解有限。
在儿童癌症幸存者研究中,对12316名5年幸存者(其中2002名有腹盆腔肿瘤,10314名无腹盆腔肿瘤)和4023名同胞参与者进行评估,以确定癌症诊断后5年或更长时间发生的需要手术治疗的肠梗阻(IOS)情况。以第二原发性恶性肿瘤、晚期复发和死亡作为竞争风险计算IOS的累积发病率。使用分段指数模型,我们评估了临床和人口统计学因素与IOS发生率之间的关联。
165名幸存者(IOS时的中位年龄为19岁;范围为5至50岁;从诊断到IOS的中位时间为13年)和14名同胞报告发生了晚期IOS。在有腹盆腔肿瘤的幸存者中,35岁时晚期IOS的累积发病率为5.8%(95%CI,4.4%至7.3%),在无腹盆腔肿瘤的幸存者中为1.0%(95%CI,0.7%至1.4%),在同胞中为0.3%(95%CI,0.1%至0.5%)。在幸存者中,腹盆腔肿瘤(调整后的发病率比[ARR]为3.6;95%CI,1.9至6.8;P<.001)和癌症诊断后5年内的腹盆腔放疗(ARR为2.4;95%CI,1.6至3.7;P<.001)增加了晚期IOS的发生率,并对诊断年份、性别、种族/族裔、诊断时年龄、随访期间年龄(作为自然立方样条)、癌症类型以及癌症诊断后5年内的化疗、放疗和手术进行了调整。发生晚期IOS会增加幸存者随后的死亡率(ARR为1.8;95%CI,1.1至2.9;P=.016),并对相同因素进行了调整。
IOS的长期风险及其与随后死亡率的关联强调了有必要提高患者和医疗服务提供者对这种并发症的认识。